TDP Biotherapeutics, Inc.
TDP is developing an anticancer drug that inhibits cancer and leaves normal cells unharmed. Product is ready for Pharm/Tox then Orphan IND.
TDP Biotherapeutics holds the exclusive license to a highly targeted anticancer drug that interferes with a protein manifested by cancer cells but not by normal cells. The synthesis, formulation, manufacturing methods, in vivo proof of concept, BA/PK are all complete. The company seeks $1.5 million to bring the product through IND enabling Pharm/Tox before initiating a first in human study in an orphan indication.